News Releases | Insmed Incorporated

Month Year

Email Alerts

Dec 13, 2006

Insmed Announces Positive IPLEX(TM) Product Information At GRS-IGF Society Meeting in Kobe, Japan

Read more
Dec 7, 2006

Insmed to Host Litigation Update Conference Call

Read more
Dec 6, 2006

Insmed Patent Litigation Verdict Announced

Read more
Nov 21, 2006

Insmed to Present at Upcoming Investor Conference in NYC

Read more
Nov 3, 2006

Insmed Incorporated Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2006

Read more
Oct 31, 2006

Insmed Inc. to Announce 2006 Third Quarter Financial Results

Read more
Oct 31, 2006

Jody LoMenzo Named Director, Investor Relations and Corporate Communications

Read more
Oct 30, 2006

Insmed to Present at Upcoming Conferences

Read more
Oct 25, 2006

Former Amgen Manufacturing Executive Joins Insmed

Read more
Oct 24, 2006

Insmed Announces Addition of Top 25 Patent Lawyer to Litigation Team

Read more
Oct 17, 2006

Insmed to Present at the BIO Investor Forum Meeting

Read more
Oct 16, 2006

Insmed Sues Tercica for False Advertising

Read more
Oct 5, 2006

Insmed Provides Update Concerning Virginia Unfair Competition Litigation

Read more
Sep 6, 2006

Insmed to Present at the BioCentury NewsMakers in the Biotech Industry Conference

Read more
Aug 8, 2006

Insmed Incorporated Reports Financial Results for the First Half and Second Quarter Ended June 30, 2006

Read more
Aug 7, 2006

Insmed Inc. to Webcast 2006 Second Quarter Financial Results Conference Call, Tuesday, August 8, 2006 at 4:30 p.m. (ET)

Read more
Jul 31, 2006

Phyton Biotech Signs Development Agreement With Insmed

Read more
Jul 19, 2006

Insmed Inc. to Webcast 2006 Second Quarter Financial Results Conference Call, Tuesday, August 8, 2006 at 4:30 p.m. (ET)

Read more
Jul 11, 2006

Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Read more
Jul 5, 2006

European Medicines Agency Validates Insmed's Regulatory Application For Marketing IPLEX(TM) in Europe

Read more
Jul 5, 2006

Court Decision Means That Patent Dispute between Insmed and Tercica and Genentch Will Have to Be Resolved at Trial

Read more
Jun 27, 2006

Insmed Presents Positive IPLEX(TM) Data At ENDO 2006

Read more
Jun 22, 2006

Insmed Endocrine Society 2006 Update; Insmed Will Report Efficacy of IPLEX(TM) in Patients with Severe Insulin Resistance; Company Also to Present Data on the Unique Pharmacokinetics of IPLEX

Read more
Jun 13, 2006

Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed

Read more
Jun 9, 2006

Insmed Provides Update on IPLEX(TM) Launch; Company Shares Details on Payer Usage Program and Pricing

Read more
May 25, 2006

INSMED Announces IPLEX(TM) Availability Nationwide for Children with Severe Short Stature; IPLEX Launch Marked By The First Product Shipments To Patients in States Across the Country

Read more
May 12, 2006

Insmed Incorporated to Present at the Rodman & Renshaw 3rd Annual Healthcare Conference

Read more
May 8, 2006

Insmed Incorporated Reports Financial Results for the First Quarter Ended March 31, 2006

Read more
May 2, 2006

Insmed Inc. to Webcast 2006 First Quarter Financial Results Conference Call, Monday May 8, 2006 at 4:30 p.m. (ET)

Read more
May 1, 2006

IPLEX(TM) Demonstrates Significant, Dose-Dependent Increases in Growth Rate

Read more
Apr 26, 2006

Insmed Announces Podium Presentation at the Pediatric Academic Societies' 2006 Annual Meeting

Read more
Apr 25, 2006

NORD Honors Insmed for Role in Developing Treatments for Rare Diseases

Read more
Mar 22, 2006

Insmed Announces Additional Information in Compliance with NASDAQ Rules

Read more
Mar 15, 2006

Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares

Read more
Mar 10, 2006

Insmed Prices $40 Million Equity Offering

Read more
Mar 6, 2006

Insmed Incorporated Announces Proposed Public Offering of Common Stock

Read more
Mar 2, 2006

Insmed Incorporated Reports Financial Results for the Fourth Quarter and Twelve-Months of 2005

Read more
Feb 23, 2006

Insmed to Announce 2005 Fourth Quarter and Year End Financial Results; Thursday, March 2

Read more
Feb 3, 2006

Insmed Incorporated Files Shelf Registration Statement

Read more
Jan 4, 2006

U. of Rochester Initiates Phase 2 Clinical Trial of Insmed's iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants

Read more
Dec 12, 2005

FDA Approves Insmed's Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency

Read more
Dec 8, 2005

Insmed Responds to Complaint Filed by Tercica

Read more
Nov 28, 2005

Insmed to Present at the Lazard Capital Markets Life Sciences Conference

Read more
Nov 5, 2005

Insmed Incorporated Reports Financial Results for the Third Quarter and First Nine Months of 2005

Read more
Nov 2, 2005

Insmed to Present at the Rodman and Renshaw 7th Annual Healthcare Conference

Read more
Nov 1, 2005

Insmed to Release Third Quarter Financial Results; Thursday, November 3

Read more
Oct 25, 2005

Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance

Read more
Oct 25, 2005

FDA to Review Insmed's Complete Response to Approvable Letter for iPlex

Read more
Oct 24, 2005

Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference

Read more
Oct 18, 2005

Insmed to Present at the BIO Investor Forum Conference

Read more
Oct 17, 2005

Insmed Submits Response to FDA Approvable Letter for iPlex

Read more
Sep 29, 2005

Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release

Read more
Sep 29, 2005

Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency

Read more
Sep 25, 2005

Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST

Read more
Sep 24, 2005

Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director

Read more
Sep 19, 2005

SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France

Read more
Aug 8, 2005

Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005

Read more
Aug 2, 2005

Insmed to Release Second Quarter Financial Results; Monday, August 8

Read more
Jun 10, 2005

FDA Extends PDUFA Date for SomatoKine to October 03, 2005

Read more
May 31, 2005

Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome

Read more
May 25, 2005

Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005

Read more
May 24, 2005

Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica

Read more
May 19, 2005

Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005

Read more
May 17, 2005

Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer

Read more
May 10, 2005

Insmed Incorporated Reports Financial Results for First Quarter of 2005

Read more
May 5, 2005

Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)

Read more
Apr 26, 2005

Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance

Read more
Apr 20, 2005

Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)

Read more
Apr 18, 2005

Patent Infringement Suit Against Insmed Dismissed

Read more
Apr 13, 2005

FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Read more
Mar 16, 2005

Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004

Read more
Mar 15, 2005

Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16

Read more
Mar 15, 2005

Insmed Announces Completion of $35 Million Financing

Read more
Mar 10, 2005

FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Read more
Feb 22, 2005

Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims

Read more
Feb 16, 2005

Insmed Provides Response to UK Patent Lawsuit

Read more
Jan 7, 2005

University of Rochester Awarded $6.5 Million to Study Efficacy OF rhIGF-I/rhIGFBP-3, SomatoKine, in the Treatment of Myotonic Dystrophy

Read more
Jan 3, 2005

Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

Read more
Dec 31, 2004

Insmed Completes New Drug Application -NDA- for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome; Conference Call Scheduled for 11:00 am January 5, 2005

Read more
Dec 30, 2004

Insmed Incorporated Released the Following Statement in Response to Recent Actions by Tercica, Inc.

Read more
Dec 21, 2004

Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.

Read more
Nov 9, 2004

Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine

Read more
Nov 8, 2004

Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock

Read more
Nov 8, 2004

Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004

Read more
Oct 26, 2004

Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live

Read more
Oct 21, 2004

Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories

Read more
Oct 19, 2004

Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor

Read more
Sep 13, 2004

Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology

Read more
Sep 8, 2004

Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein

Read more
Aug 17, 2004

Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit

Read more
Jul 28, 2004

Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004

Read more
Jul 21, 2004

Insmed to Report Second Quarter Financial Results;Wednesday, July 28

Read more
Jul 20, 2004

Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months

Read more
Jul 19, 2004

Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program

Read more
Jul 19, 2004

Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE

Read more
May 13, 2004

Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials

Read more
May 11, 2004

Insmed to Present at Rodman and Renshaw Healthcare Conference May 13, 2004; Presentation to Be Webcast Live

Read more
May 5, 2004

Insmed Incorporated Reports Financial Results for First Quarter of 2004

Read more
Apr 29, 2004

Insmed Incorporated to Webcast First Quarter Earnings Conference Call; Thursday, May 6, at 11:00 a.m. ET - 10:00 a.m. CT

Read more
Apr 14, 2004

Insmed Acquires Manufacturing Facility from Baxter International

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer